Previous 10 | Next 10 |
2024-03-28 12:38:28 ET More on Solid Biosciences Solid Biosciences: DMD Treatment Advancement With Next-Generation Capsid Piper Sandler upgrades Solid Biosciences to overweight Solid Biosciences reports Q4 results Seeking Alpha’s Quant Rating on Solid ...
2024-03-27 21:38:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
CHARLESTOWN, Mass., March 27, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced that Bo Cumbo, President and Chief Executive Officer, and Gabriel Brooks, ...
2024-03-13 16:42:19 ET More on Solid Biosciences Solid Biosciences: DMD Treatment Advancement With Next-Generation Capsid Solid Biosciences reports Q4 results Solid Biosciences signs agreement with Armatus Bio for AAV-SLB101 Seeking Alpha’s Quant Ratin...
2024-03-13 13:46:03 ET More on Catalyst Pharmaceuticals Catalyst Pharmaceuticals, Inc. (CPRX) Q4 2023 Earnings Call Transcript Biotech And Pharma Diversification Pays Off Catalyst Pharmaceuticals At A Crossroads: Firdapse Litigation And Agamree's Launch Catal...
2024-03-13 10:00:21 ET More on Health Care Select Sector SPDR XLV: Low-Cost Exposure To A Defensive Sector, While Achieving Strong Performance Healthcare In 2024: Navigating The Biopharma Bull Run XLV Likely Back To Outperforming Waters, Moderna most shorted ...
2024-03-13 09:33:36 ET More on Solid Biosciences Solid Biosciences: DMD Treatment Advancement With Next-Generation Capsid Solid Biosciences reports Q4 results Read the full article on Seeking Alpha For further details see: Solid Biosciences files $300M mi...
— Company ends 2023 with approximately $123.6 million in cash and investments. Combined with gross proceeds from $108.9 million private placement in January, Solid has anticipated cash runway into 2026 — — FDA cleared IND and granted Fast Track Designation and Orpha...
2024-03-07 20:06:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-03-07 07:10:11 ET More on Solid Biosciences Solid Biosciences: DMD Treatment Advancement With Next-Generation Capsid Solid Biosciences wins FDA orphan status for gene therapy (update) Solid Biosciences raises $109M through private placement Seeking Alpha...
News, Short Squeeze, Breakout and More Instantly...
Solid Biosciences Inc. Company Name:
SLDB Stock Symbol:
NASDAQ Market:
Solid Biosciences Inc. Website:
CHARLESTOWN, Mass., July 01, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced a grant of 11,847 restricted stock units (“...
CHARLESTOWN, Mass., July 01, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced that the Company has been added to the broad-market Russell 3000 ® Index as ...
2024-06-21 08:15:07 ET Piper Sandler analyst issues OVERWEIGHT recommendation for SLDB on June 21, 2024 06:49AM ET. The previous analyst recommendation was Overweight. SLDB was trading at $6.3 at issue of the analyst recommendation. The overall analyst consensus : BUY. ...